A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
Status:
Completed
Trial end date:
2017-11-09
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug known
as baricitinib in participants with systemic lupus erythematosus.